Análisis coste-efectividad y coste-utilidad de apixaban frente a dabigatrán y rivaroxaban en el tratamiento y prevención secundaria del tromboembolismo venoso
详细信息 查看全文
- 作者：Fernando de Andrés-Nogales ; Itziar Oyagüez…
- 关键词：Palabras claveApixaban ; Anticoagulante ; Coste ; utilidad ; Embolia pulmonar ; Tromboembolismo venoso ; Trombosis venosa profunda
- 刊名：PharmacoEconomics Spanish Research Articles
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：14
- 期：1
- 页码：7-18
- 全文大小：1078KB
- 刊物主题：Pharmacy;
- 出版者：Springer International Publishing
- ISSN：1989-5453
- 卷排序：14
文摘
ObjectiveCost-utility analysis of a 6-month treatment of apixaban (10 mg/12 h, first 7 days; 5 mg/12 h, afterwards) for the treatment of the first event of venous thromboembolism (VTE) and prevention of recurrences, versus dabigatran (150 mg/12 h) after 5 days taking low molecular weight heparins (LMWH/dabigatran) and versus rivaroxaban (15 mg/12 h, the first 21 days; 20 mg/day, afterwards).